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The contamination of the environment with human pharmaceuticals is widespread and demand for such pro-
ducts is mounting globally. Wild vertebrates may be at particular risk from any eﬀects from pharmaceuticals,
because of the evolutionary conservation of drug targets. However, exposure of wildlife to pharmaceuticals is
poorly characterised, partly due to challenges associated with detecting rapidly metabolised compounds. As part
of a wider study on the behavioural eﬀects of ﬂuoxetine (Prozac) on Eurasian starlings (Sturnus vulgaris), we
investigated which avian samples are best suited for detecting exposure to ﬂuoxetine in free-living birds. We
analysed plasma, various tissues and tail feathers (grown both in the wild and in captivity during the dosing
period) from ﬂuoxetine-treated birds (dosed daily with 0.035mg kg−1 bodyweight for 28weeks), and liver
tissue and tail feathers from sham-dosed birds. We detected ﬂuoxetine in only two of twelve plasma samples
from dosed birds. In dosed birds, median concentrations of free ﬂuoxetine/norﬂuoxetine in tissues (two hour
post-ﬁnal dose) were: 111.2/67.6 ng g−1 in liver, 29.6/5.7 ng g−1 in kidney, 14.2/4.0 ng g−1 in lung, 15.1/
1.6 ng g−1 in brain. We estimated that ﬂuoxetine would remain detectable in liver and kidney approximately 4.5
times longer (90 h) than in brain (20h). In dosed birds, ﬂuoxetine was detected in feathers regrown during the
dosing period (median concentration=11.4 ng g−1) at concentrations signiﬁcantly higher than in regrown
feathers from control birds. Fluoxetine residues were detected in wild-grown feathers (grown before the birds
were brought into captivity) at concentrations up to 27.0 ng g−1, providing some evidence of likely exposure in
the wild. Our results show liver and kidney can be used for detecting ﬂuoxetine in avian carcasses and provide a
ﬁrst indication that feathers may be useful for assessing exposure to ﬂuoxetine, and possibly other pharma-
ceuticals.
1. Introduction
Over the past decades, the widespread occurrence of human phar-
maceuticals in the environment has increasingly come to light
(Daughton and Ternes, 1999). The amounts discharged to the en-
vironment are likely to increase further over the coming years
(QuintilesIMS Institute, 2016). Human pharmaceuticals have been de-
tected in both aquatic and terrestrial ecosystems and biota (Hughes
et al., 2013; Monteiro and Boxall, 2010) and, although concentrations
are typically low relative to therapeutic doses, they may yet pose a
threat to biota as they are designed to be biologically active at low
concentrations (Boxall, 2004). Free-living vertebrates are predicted to
be particularly at risk from human pharmaceutical exposure due to the
degree of orthology between humans and other vertebrates
(Gunnarsson et al., 2008). However, there is relatively little
understanding of the extent to which higher vertebrates, such as birds,
are exposed to human pharmaceuticals. Potential exposure routes in-
clude ingestion of contaminated invertebrates at wastewater treatment
plants, consumption of contaminated ﬁsh and scavenging on con-
taminated carcasses (Shore et al., 2014). The concentrations of phar-
maceuticals associated with these exposure routes can be suﬃcient to
exert sub-lethal eﬀects on avian ﬁtness (Bean et al., 2014; Whitlock
et al., 2018) or, under rare circumstances, can cause mortality (Oaks
et al., 2004).
The selective serotonin reuptake inhibitor (SSRI) ﬂuoxetine
(Prozac), prescribed as an antidepressant in people, has received con-
siderable attention regarding its eﬀects on wildlife. Its active de-
methylated metabolite, norﬂuoxetine, is also a SSRI and similarly
considered to pose an environmental risk, albeit to a lesser extent
(Kumar and Xagoraraki, 2010). Fluoxetine and norﬂuoxetine have both
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been detected in freshwater ﬁsh tissues and plasma, generally at micro
to nanogram per gram concentrations (Brooks et al., 2005; Chu and
Metcalfe, 2007; Schultz et al., 2010), but relatively little is known about
subsequent trophic transfers. A recent study on an estuarine/riverine
food web detected trace amounts of ﬂuoxetine in all water and some
ﬁsh plasma samples but not in osprey (Pandion haliaetus) plasma (Bean
et al., 2018). However, detecting exposure is likely to be more chal-
lenging for higher trophic terrestrial wildlife than for ﬁsh. This is be-
cause ﬁsh in eﬄuent-dominated freshwaters may be continually living
in dilute concentrations of ﬂuoxetine/norﬂuoxetine (Christensen et al.,
2009) and such ongoing, chronic exposure may result in a persistence
presence of residues in plasma. In contrast, non-aquatic higher verte-
brates are likely to be exposed to pharmaceuticals more sporadically
when they consume contaminated prey, water or vegetation. Ability to
detect exposure to compounds that have short plasma and tissue half-
lives, such as ﬂuoxetine, will be highly dependent on the magnitude
and timing of exposure relative to sampling. False negatives (non-de-
tection of residues because individuals have metabolised the compound
before it can be measured) are likely to be common.
Characterising contaminant exposure speciﬁcally in wild birds can
involve measuring residues in various types of sample (Espin et al.,
2016). Plasma is probably the most frequently taken non-destructive
sample, generally collected to determine circulating concentrations
and/or provide evidence of recent exposure. However, it is clear from
the multitude of human studies that the plasma half-life of many
pharmaceuticals can be short. Elimination in birds may occur even
more quickly than in humans; for example, studies with another SSRI,
paroxetine, found that the plasma half-life in grey parrots (Psittacus
erithacus) given therapeutic doses was 5.4 h compared to 21 h in hu-
mans (van Zeeland et al., 2013). Environmental concentrations of
pharmaceuticals to which wild birds are likely to be exposed are also
typically orders of magnitude lower than therapeutic doses. This com-
bination of low exposure and fast metabolism suggests that the reduc-
tion of compound to concentrations too small to be detected is likely to
be rapid in birds (Caccia et al., 1990). Consistent with this, a recent
study found that neither ﬂuoxetine nor norﬂuoxetine were detected in
the plasma of any of 12 Eurasian starlings (Sturnus vulgaris) 2 h after
they were given a sub-therapeutic dose (1.58 μg per bird) of ﬂuoxetine
(Bean et al., 2017). Although faecal sampling is another non-destructive
sample that can be taken, faecal elimination of pharmaceuticals can
likewise be rapid (Bean et al., 2017) and obtaining suitable faecal
samples from wild-caught birds can be problematic.
Exposure to contaminants in wild birds is also characterised by
analysing tissues from individuals found dead (Espin et al., 2016;
Gómez-Ramírez et al., 2014). As with plasma, the suitability of such
measurements for pharmaceuticals depends on dose and tissue half-life;
the latter is still likely to be rapid and shorter for pharmaceuticals than
for more persistent contaminants that are more commonly monitored
(Gómez-Ramírez et al., 2014). Elimination half-lives for ﬂuoxetine may
be longer in tissues than in plasma (Bean et al., 2017) but avian tissue
distribution and persistence is not well characterised. Feathers are also
used for detecting contaminant exposure. Residues can be the result of
past exposure that occurred at the time of feather growth (Espin et al.,
2016), as circulating plasma contaminant concentrations are stored
within the feather as it grows and remain stable therein over long
periods of time (Garcia-Fernandez et al., 2013). Feather analysis has
been used to demonstrate exposure to a range of contaminants (Garcia-
Fernandez et al., 2013; Abdullah et al., 2015; Espin et al., 2012), al-
though, in some cases, contamination may be on the feather surface
where lipophilic contaminants have been expressed in preen oil
(Jaspers et al., 2008). Feathers can be collected from carcasses and non-
destructively from live birds through plucking, whilst moulted feathers
can be collected from nests (Garcia-Fernandez et al., 2013). We are
unaware of any published data on the transport of ﬂuoxetine and
norﬂuoxetine into feathers but it is known that ﬂuoxetine is deposited
in mammalian hair (Lefebvre et al., 1999; Fisichella et al., 2014), and is
found in poultry feather meal, presumably a result of treating poultry
with veterinary feed additives (Love et al., 2012).
Detection of exposure is key for understanding whether pharma-
ceuticals could pose a signiﬁcant direct risk to wildlife. The main aim of
this paper was to characterise which avian tissue samples are best
suited for detecting ﬂuoxetine exposure in free-living birds. We quan-
tiﬁed and compared free concentrations of ﬂuoxetine and norﬂuoxetine
in a range of tissues (plasma, brain, kidney, liver and lung) taken from
wild Eurasian starlings held untreated in captivity (during which time
they would have metabolised any existing plasma and internal tissue
residues) and subsequently dosed chronically with an environmentally-
relevant dose of ﬂuoxetine. We used starlings as they are known to feed
on invertebrates in trickling ﬁlter beds at waste water treatment plants
(WWTPs) (Fuller and Glue, 1978) and so are at high risk of exposure to
pharmaceuticals present in sewage, such as ﬂuoxetine (Lajeunesse
et al., 2012). We coupled our measured concentrations to ﬂuoxetine
tissue decay curves developed in a previous study (Bean et al., 2017) to
determine the time period over which tissue residues were likely to be
analytically detectable; such information is crucial for informing the
design of biomonitoring programmes. We also quantiﬁed the levels of
free ﬂuoxetine and norﬂuoxetine in feathers from the same birds. These
samples comprised: (i) feathers regrown during the period in which
birds were chronically dosed, thereby providing a test of whether
feathers accumulate ﬂuoxetine in birds known to have been exposed;
(ii) feathers grown by the birds before they were captured - detection of
ﬂuoxetine in these feathers would provide some evidence that starlings
are currently exposed to ﬂuoxetine in the wild in Britain.
2. Methods
2.1. Ethics statement
The birds used in the study were captured under licences from the
British Trust for Ornithology and Natural England. The aviary study and
all experimental protocols conducted therein were assessed and ap-
proved by ethics committees at the University of York (UK) and the
Animal and Plant Health Agency. The work was carried out under
Home Oﬃce licence, number PPL 60/4213.
2.2. Aviary study
The samples analysed were from birds that underwent an in vivo
chronic eﬀects experiment. These were 28 wild-caught Eurasian star-
ling (Sturnus vulgaris), captured under licence in October 2015 from a
site in North Yorkshire (UK). The captive birds were housed in ﬁve
outdoor aviaries in single sex groups (three aviaries containing 7, 6 and
6 females; two aviaries with 6 and 3 males). Within each aviary, in-
dividuals were allocated randomly to either ﬂuoxetine treatment or
control treatment (n=14 per group), within the constraint that num-
bers in each treatment group were balanced as closely as possible. We
housed treated and control birds together to avoid biases in behavioural
experiments that were carried out during the chronic dosing period as
part of a wider study.
Fluoxetine-treated starlings were exposed chronically to a nominal
daily dose of 2.7 μg bird−1 ﬂuoxetine. This was equivalent to a mean
(± SD) dose of 34.3 (± 1.44) μg kg−1 bodyweight (BW) daily based
on a mean (± SD) starling weight of 78.9 (± 3.37) g across the
duration of the dosing period. The dose was calculated to be re-
presentative of an environmentally relevant exposure, based on: i) the
feeding rates for starlings, ii) ﬂuoxetine concentrations detected in in-
vertebrate prey at a waste water treatment plant (Bean et al., 2017;
Feare, 1984). We administered a ﬁve-day corrected dose of 3.8 μg
bird−1 each weekday (as birds were not dosed at weekends) in the early
afternoon, by hand-feeding individuals with a spiked waxworm (Gal-
leria mellonella) (Bean et al., 2014) containing 3.8 μg ﬂuoxetine dis-
solved in 2.5 μl deionised water. Control birds were given a waxworm
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injected with 2.5 μl deionised water only. To conﬁrm the dose ad-
ministered, we quantiﬁed the amount of free ﬂuoxetine in a subset of
spiked waxworms and the mean (± SE) concentration was
3.71 ± 0.18 μg worm−1 (n=10; see (Whitlock et al., 2018)). Dosing
of birds commenced in late November 2015 and continued for
28 weeks, at which point 24 individuals remained alive (n=12 per
group). Details of the dose calculation, animal capture and husbandry
are given in the SI.
Tail feathers (rectrices R4 and R9) were plucked (and retained as
pooled samples for each bird) from all individuals one week after
dosing commenced, except for two ﬂuoxetine-treated birds and one
control group bird that were missing R4 and/or R9. Plucking was un-
dertaken at this time, rather than before dosing was started, due to
ethical concerns associated with plucking feathers simultaneously with
other stressful procedures, such as baseline behavioural assays, blood
sampling and acclimation to captivity. The feathers, grown when the
birds were free-living in the wild (hereafter termed wild-grown
feathers), were plucked so that they would regrow during the dosing
period. This would allow us to determine whether ﬂuoxetine residues
could be detected in feathers that were regrown (hereafter termed re-
grown feathers) during a period when birds were exposed to an en-
vironmentally relevant concentration of ﬂuoxetine. We restricted our
feather analyses to two speciﬁc rectrices because contaminant con-
centrations can vary signiﬁcantly between feathers (Furness et al.,
1986; Gochfeld, 1980; Braune, 1987).
After 28 weeks of dosing, the birds were euthanised by cervical
dislocation to allow harvesting of various tissues for the determination
of free concentrations of ﬂuoxetine and norﬂuoxetine. Euthanasia of
each bird occurred 2 h after administration of the ﬁnal ﬂuoxetine/
control dose. Brain, kidney, liver and lung were immediately excised,
frozen within 30min using dry ice and subsequently stored at −80 °C
until analysis. In between administration of the ﬁnal dose and eu-
thanasia, a blood sample was taken from each ﬂuoxetine-treated bird
for analysis of free ﬂuoxetine and norﬂuoxetine plasma residues.
Guided by ﬁndings in (Bean et al., 2017), both to enhance the chance of
detecting residues and to allow decay curves to be constructed, we
blood sampled six individuals 30min after dose administration, whilst
the remaining six individuals were sampled after 1 h. Assignment of
birds to the 30 or 60min bleed was randomised, within the constraint
that sex and treatment were balanced between the timings. Blood
samples (500 μl) were collected by jugular venepuncture (23 G needle
AN-2316R, Terumo UK, Bagshot, UK, and 1ml syringe, BD, Wo-
kingham, UK), transferred to a heparinised 3.5ml Microtainer (BD,
Wokingham, UK), and centrifuged within 30min of collection at
16,000g for 10min. The plasma was then collected, transferred to a
1.5 ml polypropylene Eppendorf tube (Eppendorf UK, Stevenage, UK)
and stored at −20 °C until analysed.
The regrown R4 and R9 rectrices were also removed from each bird,
pooled (per individual) for analysis and stored in brown paper envel-
opes at room temperature. Regrown feathers were not collected from
three (two ﬂuoxetine-treated, one control) birds as their rectrices had
not regrown (SI, Table S5). Samples for analysis contained both rec-
trices from each bird except for four control samples, which contained
only one feather of the pair; in two of these four individuals, the re-
grown feather was lost or damaged before it could be harvested and in
the other two, the feather never regrew (SI, Table S5). We excluded
these birds from any statistical comparison of residue magnitude as
concentrations in a single feather may not be directly comparable to
those in a pooled pair (Bortolotti, 2010).
2.3. Analysis of samples for ﬂuoxetine residues
We screened the livers from all the control birds to determine
whether it was worthwhile analysing other tissues from individuals in
this group. Limited previous results (Bean et al., 2017) have indicated
that residues occur at higher concentrations in liver compared to other
tissues, therefore an absence of detectable liver residues was assumed to
be indicative of an absence of residues in other tissues. We could not
detect ﬂuoxetine residues in the livers of eleven of the twelve control
birds, whilst the remaining bird had a concentration close to the limit of
detection (free concentration in sample: 0.34 ng g−1, liver limit of de-
tection (LOD): 0.27 ng g−1). Free norﬂuoxetine was not detected in any
control liver sample. Consequently, we restricted further analysis of
residues in other body tissues (kidney, lung, brain) to samples taken
only from ﬂuoxetine-treated birds. We likewise only analysed plasma
samples from ﬂuoxetine-treated birds, as the aim was solely to examine
the timeframe of disappearance of residues from this labile pool.
In contrast, we analysed residues in regrown and wild-grown
feathers from both ﬂuoxetine-treated and control birds. This was to
assess: i) whether there was ﬂuoxetine in the regrown feathers of
control birds, which may have arisen from cross-contamination given
that the birds were housed in mixed-treatment groups; ii) whether there
were residues in wild-grown feathers that were indicative of past ex-
posure.
Tissue samples were thawed, cut in half, homogenised and a sub-
sample (nominal mass of 300mg for brain, kidney and liver, 100mg for
lung) was taken for analysis. Each subsample was weighed accurately to
the nearest 0.1 mg. Samples were each ground with sand in a glass
pestle and mortar before being transferred to a Pyrex test tube. Feather
samples were washed with diluted soap (1% solution of Decon 90 in
HPLC grade water; Decon Laboratories, Hove, UK). There is evidence
that surfactants can remove some proportion of lipophilic contaminant
from the feather surface (Jaspers et al., 2008). The feathers were then
washed with HPLC grade water and allowed to dry for 24 h before being
cut into small pieces and ground in ceramic pestle and mortars with
liquid N2. After grinding, the entirety of each feather sample was
transferred to a Pyrex test tube. Plasma samples were thawed to room
temperature and an 80 μl aliquot was taken from each for analysis. Four
of the twelve plasma samples had insuﬃcient volume to provide an
80 μl aliquot, so smaller volumes were taken instead (25, 60, 60 and
70 μl aliquots).
HPLC grade solvents (including HPLC grade water) were used
throughout the sample preparation and analysis process. Prior to ex-
traction, all sample types were spiked with ﬂuoxetine-d5 (98% purity,
Sigma Aldrich, Gillingham, UK) internal standard. The extraction
method was based on (Bean et al., 2017). All samples were extracted by
adding 2× 2ml portions (i.e. 4 ml total) of 0.2% formic acid in me-
thanol/water (50:50 v/v), with vortex mixing for 20–30 s after each
addition of solvent. The samples were placed in a sonication bath at
20 °C for 15min and subsequently centrifuged for 10min at 20 °C and
4696g. The supernatant was transferred to a new test tube and 8ml
water (HPLC Grade) was added, before clean-up by SPE. Following
(Grabic et al., 2012), Oasis HLB cartridges (6 cm3, 200mg sorbent,
30 μm particle size; Waters, Elstree, UK) were ﬁrst conditioned with
methanol, then water, before the sample extracts were run through
them at a ﬂow rate of 1mlmin−1. After drying at full vacuum for
30min, the samples were eluted into fresh test tubes with methanol
followed by acetonitrile, before being concentrated to dryness under a
N2 stream, in a water bath at 40 °C. The residues were then recon-
stituted in 1ml of 0.2% formic acid in water/acetonitrile (80:20 v/v),
vortex mixed and transferred to LC vials for LC-MS/MS analysis.
2.4. LC-MS/MS analysis
The residues of free ﬂuoxetine and norﬂuoxetine (i.e. the free parent
compounds only) were quantiﬁed by reverse phase LC-MS/MS. The
analytes were separated on a Thermo Scientiﬁc UltiMate 3000 HPLC
with a C18 column (Thermo Scientiﬁc Hypersil GOLD; particle size
1.9 μm, length 100mm, internal diameter 2.1 mm). The column tem-
perature was held at 30 °C and the analytes were eluted using a binary
gradient of mobile phases A (water containing 0.2% formic acid) and B
(acetonitrile containing 0.2% formic acid). The volume of injection of
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the sample extracts was 25 μl and the mobile phase ﬂow rate was as
follows: 0.35mlmin−1 from 0 to 7.5 min, 0.25mlmin−1 from 7.5 to
12min and 0.30mlmin−1 after 12min. The gradient was performed as
follows: 18% mobile phase B from 0 to 7.5 min, 60% B from 7.5 to
12min, 100% B from 12 to 15min, 18% B from 15 to 20min.
The HPLC system was coupled to a TSQ Quantum Ultra triple
quadrupole mass spectrometer. The sample extracts were ionised by
electrospray ionisation, in positive ion mode. Detection was performed
by monitoring two MS/MS transitions per analyte in selected reaction
monitoring (SRM) mode. See Table S1 in the SI for fragmentation
parameters.
For quality control in each batch we ran a reagent blank, matrix
blank and spiked control. We constructed calibration curves of the
target compounds (Sigma Aldrich, Gillingham, UK), to cover the ex-
pected analyte concentration range in the samples. Concentrations were
recovery corrected using the internal standard method (see Table S2 in
the SI for method recoveries and detection limits for ﬂuoxetine and
norﬂuoxetine).
2.5. Statistical analyses
All statistical analyses were carried out in the software package R (R
Core Team, 2016). Kruskal-Wallis non parametric tests (with Dunn's
post-hoc tests using R package “dunn.test” (Dinno, 2017)) were used to
compare the four tissue types (brain, kidney, liver, lung) in treated
individuals for free concentrations of: (i) ﬂuoxetine; (ii) norﬂuoxetine;
(iii) ﬂuoxetine:norﬂuoxetine ratio. We examined the signiﬁcance of
associations between ﬂuoxetine concentrations in diﬀerent tissues and
between ﬂuoxetine and norﬂuoxetine concentrations within tissues
using Spearman's Rank correlation coeﬃcients. Comparison of the free
ﬂuoxetine concentrations in regrown feathers between the treatment
and control groups was made by Mann-Whitney non-parametric test;
non-detected ﬂuoxetine concentrations in feathers were assigned a
value of 0.5*LOD (0.42 ng g−1). Non-parametric tests were selected due
to non-normal distribution of datasets. Total tissue burdens (sum of
parent compound and metabolite) were estimated by summing the mass
of parent ﬂuoxetine present (concentration in the tissue multiplied by
the tissue mass) and the mass of ﬂuoxetine that had been metabolised.
The latter was back-calculated using the number of moles of nor-
ﬂuoxetine in the tissue (assuming a 1:1 molar ratio with ﬂuoxetine),
itself derived using the mass of norﬂuoxetine in the tissue (concentra-
tion in the tissue multiplied by the tissue mass). We expressed the
calculated burden in each tissue as a percentage of the measured ad-
ministered oral daily dose (3.71 μg). Tissue burdens and their percen-
tage of administered dose are reported as medians with interquartile
ranges.
2.6. Estimation of time for concentrations to decay to the limit of detection
(LOD) in brain, kidney, and liver
We used concentration decay curves developed in a recent study
(Bean et al., 2017) to estimate how long the dose of ﬂuoxetine used in
the present study would remain detectable as free ﬂuoxetine and nor-
ﬂuoxetine in brain, kidney and liver. The curves were derived from in
vivo experimental data from Eurasian starlings given 1.58 μg ﬂuoxetine
bird−1, i.e. 42.6% of the dose administered in our study (Bean et al.,
2017). We assumed that the decay of residues in tissues follows a ﬁrst
order relationship (y= Ce−kx) and applied the rate constants (k) from
(Bean et al., 2017) to the mean concentration of ﬂuoxetine (y) at 2 h (x)
measured in the present study (in brain, kidney and liver), allowing the
estimation of C for each tissue. We then plotted the decay curves and
derived the time (x) when C would be equal to the limit of detection
(LOD) for each tissue type.
3. Results and discussion
3.1. Free concentrations and distribution of ﬂuoxetine and norﬂuoxetine
within the body of ﬂuoxetine-treated birds
Fluoxetine was detected in two of the six plasma samples taken from
ﬂuoxetine treated birds 30min after administration of the ﬁnal oral
dose (free concentration 0.20 and 0.42 ngml−1 respectively) but was
not detected any of the plasma samples (n=6) taken 60minute post-
dose. Norﬂuoxetine was not detected in any of the plasma samples at
either time point. Because of this very rapid elimination relative to our
sampling times, we were unable to construct a simple plasma decay
curve, as we had originally planned. However, our results indicate that
plasma elimination of ﬂuoxetine is faster in starlings than previously
thought. A previous study using a lower dose (1.58 μg per bird) found
no detectable ﬂuoxetine or norﬂuoxetine in plasma after 2 h (Bean
et al., 2017) but our data indicate that a (> 2 fold) higher dose is
completely eliminated from plasma within 1 h. Clearance may also be
faster than might be predicted from mammalian studies (which form
the bulk of available pharmacokinetic data for pharmaceuticals), as the
metabolic rates of certain passerines and psittaciformes can exceed
those of comparably sized mammals (i.e. rodents) (McNab, 1988) and
of humans (van Zeeland et al., 2013). Given that only small volumes of
plasma can be collected non-destructively from many birds due to their
low body mass and given the apparently short window for successful
detection of ﬂuoxetine post-exposure, we conclude that avian plasma is
of severely limited use for determining exposure of wild birds to
ﬂuoxetine.
Concentrations of free ﬂuoxetine and norﬂuoxetine were both de-
tected in the brain, kidney, liver and lung of each of the ﬂuoxetine-
treated birds. Fluoxetine is relatively lipophilic and has a large volume
of distribution in mammalian tissues (Caccia et al., 1990; Hiemke and
Hartter, 2000) and this also appears to be true in birds. In the present
study, concentrations of parent compound and metabolite varied sig-
niﬁcantly between tissue types (H(3)≥ 32.5, p < 0.001 for ﬂuoxetine
and norﬂuoxetine). Post-hoc tests indicated that free ﬂuoxetine con-
centrations decreased in the order liver > kidney≥ lung≥ brain
(Fig. 1a and SI, Table S3) and free norﬂuoxetine concentrations in the
order liver > kidney≥ lung > brain (Fig. 1b and SI, Table S3). These
results clearly indicate that ﬂuoxetine and its metabolite distribute
unevenly between tissues and that the highest concentrations of free
compound are found in the liver. A limited previous study in which
birds were dosed at half the rate to the present study had also suggested
that free residues may be highest in the liver, but residues had been
quantiﬁed in only three birds (Caccia et al., 1990). When tissue ﬂuox-
etine burdens were calculated for the present study, the magnitude of
distribution to each tissue followed a similar pattern to the observed
concentrations of ﬂuoxetine (Table 1). On average, the equivalent of
8.59% of the ﬁnal dose (given 2 h earlier) was accounted for by the total
burden of free compound in the four tissues, with most (7.40%) in the
liver (Table 1). We also examined the relationships between ﬂuoxetine
concentrations in diﬀerent organs to determine whether residues in one
tissue could be used to predict concentrations in others. There were
positive relationships in all cases but only the correlation between brain
and kidney ﬂuoxetine was statistically signiﬁcant (Fig. 2 and SI, Table
S4). Thus, it might be possible to use information on ﬂuoxetine levels in
the kidney to predict ﬂuoxetine concentrations in the brain, the target
organ for this compound, although such estimates would be approx-
imate.
Based on our concentration data and because of the relatively large
mass that can be harvested for analysis, liver and kidney would appear
to be the most appropriate tissues for biomonitoring ﬂuoxetine ex-
posure in starlings and potentially other wild birds. Measuring kidney
concentrations may also provide a means for predicting brain con-
centrations, whilst liver concentrations are likely to be higher than in
kidney, lung or brain tissue. However, liver, and particularly kidney,
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may not be the best choice of organs for monitoring exposure in other
vertebrate wildlife, such as wild mammals. Mammalian studies have
shown that ﬂuoxetine is distributed extensively in liver, lung and brain
tissues (Caccia et al., 1990; Pohland and Bernhard, 1997; Johnson et al.,
2007), primarily to the lysosome-rich lung and liver tissues (Daniel and
Wojcikowski, 1997), but with less distribution to the kidney. For ex-
ample, a study that analysed concentrations of ﬂuoxetine and nor-
ﬂuoxetine in deceased human pilots that had taken antidepressant
medication found that distribution coeﬃcients in tissues decreased in
the following order for both compounds: lung > liver > brain >
kidney (Johnson et al., 2007). Further studies are needed to determine
which may be the best organs for biomonitoring ﬂuoxetine exposure
across the range of wildlife taxa.
We also examined the ratio of free ﬂuoxetine to norﬂuoxetine in the
dosed starlings and found that this also diﬀered signiﬁcantly with tissue
type (Kruskal-Wallis: H=32.23, 3 d.f., p < 0.001; Fig. 1c). However,
within kidney, liver and lung tissue, ﬂuoxetine and norﬂuoxetine con-
centrations were signiﬁcantly correlated with each other (Fig. 3 and SI,
Table S4). A similar relationship was apparent in brain but did not
achieve statistical signiﬁcance (Fig. 3 and SI, Table S4). The median
ﬂuoxetine:norﬂuoxetine ratio in starling brain tissue was 7.81. This
ratio appears to be very diﬀerent to that recorded in an earlier mammal
study, in which rats were given a single oral dose of 5mg kg−1 ﬂuox-
etine (two orders of magnitude larger than the dose used in the present
study), leading to a mean ﬂuoxetine:norﬂuoxetine ratio in rat brain of
0.26 (here calculated as the inverse of a stated norﬂuoxetine:ﬂuoxetine
ratio of 3.8 (Caccia et al., 1990)). Although the ratio in rat brain in-
creased with dose, with ﬂuoxetine:norﬂuoxetine ratios of 1 and 1.4
(inverse of stated norﬂuoxetine:ﬂuoxetine ratios of 1 and 0.7) in rats
given ﬂuoxetine doses of 10 and 20mg kg−1 respectively (Caccia et al.,
1990), these were still much lower than the median brain tissue ratio of
7.81 for starlings in the present study. Even though we dosed the
starlings chronically rather than administering a single dose, we esti-
mated that ﬂuoxetine would likely be cleared from the brain after ap-
proximately 20 h (see below), limiting the potential for ﬂuoxetine to
accumulate in brain tissue as a result of successive, chronic dosing. Our
results suggest that the ratio of ﬂuoxetine:norﬂuoxetine in the brain
may be higher in birds compared to mammals following low doses of
ﬂuoxetine. This may indicate that birds are more susceptible to adverse
eﬀects on behaviour than mammals following exposure in the en-
vironment, since the R-form of ﬂuoxetine is a more potent inhibitor of
serotonin reuptake than R-norﬂuoxetine, although this diﬀerence in
activity between parent and active metabolite is not observed in the
respective S-enantiomers (Fuller et al., 1992).
3.2. Decay of ﬂuoxetine in avian tissues following oral exposure
Based on decay curves derived from those given in (Bean et al.,
2017), the times taken for organ concentrations to decay to the detec-
tion limit in the present study were estimated to be 20 h for brain, 90 h
for kidney and 93.5 h for liver (Fig. 4). This calculation conﬁrms that
liver or kidney are likely to be preferred organs for biomonitoring ex-
posure because residues persist for longer than in the brain, in which
ﬂuoxetine parent compound arising from environmentally-relevant
exposures would be eliminated in less than a day. These estimates of
time to reach detection limits are however only approximate, as our
Fig. 1. Median free concentrations of (a) ﬂuoxetine and (b)
norﬂuoxetine in brain, kidney, liver and lung (n=12 per
organ). In (a) and (b), signiﬁcant diﬀerences in concentrations
between pairs of tissues are starred (*p < 0.05, **p < 0.01,
***p < 0.001). See SI, Table S3 for full statistical test results,
based on Dunn's test. Plot (c) shows the median ratio of
ﬂuoxetine to norﬂuoxetine (i.e. concentration of ﬂuoxetine
divided by concentration of norﬂuoxetine) in each tissue.
Each plot corresponds to concentrations of residues 2 h after
the ﬁnal dose (3.71 μg bird−1) of a 28-week dosing period.
Boxes correspond to upper and lower quartiles and points
shown outside of whiskers are outliers (1.5*IQR, as deﬁned by
Tukey (1977)).
Table 1
Median free ﬂuoxetine tissue burdens (in ng) estimated for brain, kidney, liver
and lung; shown with interquartile range (IQR). n=12 per organ. Table also
expresses the burdens as median percentages of the total oral dose (3.71 μg),
with corresponding IQRs shown.
Tissue Median burden/IQR (ng) Median percentage of dose/IQR (%)
Brain 14.5/11.8–15.3 0.390/0.318–0.414
Kidney 18.9/12.5–28.4 0.509/0.338–0.766
Liver 274/215–396 7.40/5.80–10.7
Lung 10.9/9.48–19.8 0.293/0.255–0.534
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calculations suggest that ﬂuoxetine persists in liver and kidney for>
24 h and therefore would have been bioaccumulated to some extent
over the course of the dosing period that we used. Thus, time to reach
detection limit will in part be a function of dosing duration. Never-
theless, our data provide evidence that analysis of kidney and especially
liver tissue may allow ﬂuoxetine residues to be detected in the organs of
dead wild birds. As the brain is the intended site of therapeutic action
for ﬂuoxetine, presence in wild bird brain tissue might be expected to
indicate a degree of risk from adverse eﬀects, such as behaviour al-
teration (Bean et al., 2014; Whitlock et al., 2018). Yet according to our
decay curve estimates, residues in avian brain drop to undetectable
concentrations rapidly compared to those in liver and kidney tissue.
3.3. Free concentrations in regrown and wild-grown feathers
Fluoxetine was detected in all the regrown rectrice feathers ana-
lysed from ﬂuoxetine-treated individuals (11/11) and in all but two of
the regrown feather samples from control individuals (6/8). Such fre-
quent detection of ﬂuoxetine in the regrown feathers of control birds
was unexpected. It suggested that contact with excreta and possibly
preen oil from dosed birds may have led to surface contamination of
feathers in control birds. Although all feathers were thoroughly washed
with mild soap, previous studies have found that washing is not always
able to fully remove contaminant residues from feather surfaces
(Garcia-Fernandez et al., 2013; Jaspers et al., 2008; Cardiel et al.,
2011). However, it is noteworthy that an earlier study found that
washing feathers with a surfactant removed at least some external re-
sidues of lipophilic persistent organic pollutants, likely those derived
from preen oil (Jaspers et al., 2008). The surfactant we used may have
likewise reduced external feather ﬂuoxetine contamination from preen
oil, although this may have been less eﬀective than for the persistent
organic pollutants in (Jaspers et al., 2008), as ﬂuoxetine is less lipo-
philic. It is also possible that contamination arose from control birds
ingesting food and water containing ﬂuoxetine-contaminated faeces (or
even consuming contaminated faces directly), resulting in circulating
ﬂuoxetine residues in the plasma and subsequent deposition into
growing feathers. Such contamination was possible as the experimental
design of our wider behavioural studies necessitated housing starlings
in mixed treatment groups.
Whilst we were unable to determine whether residues in control
Fig. 2. Scatter plots of free ﬂuoxetine concentrations between pairs of diﬀerent tissues. Spearman correlation coeﬃcients are shown, as are corresponding p-values
for statistically signiﬁcant correlations, whilst non-signiﬁcant correlations are ascribed a p-value of “ns” (α=0.05). Speciﬁcally, plots show correlations between: a)
liver and kidney ﬂuoxetine, b) liver and lung ﬂuoxetine, c) liver and brain ﬂuoxetine, d) kidney and lung ﬂuoxetine, e) kidney and brain ﬂuoxetine, f) lung and brain
ﬂuoxetine. Note that full results from Spearman's Rank-Order correlations are reported in the SI, Table S4.
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Fig. 3. Scatter plots of ﬂuoxetine and norﬂuoxetine free concentrations (ng g−1) within each tissue: a) liver, b) kidney, c) lung and d) brain. Spearman correlation
coeﬃcients are also displayed.
Fig. 4. Decay curves that estimate the concentration of free
ﬂuoxetine in various tissues (brain, liver, kidney) over time
(hours) post exposure (n=12 birds per tissue). Curves
generated using rate constants derived in another study,
during an in vivo experiment (Bean et al., 2017). The black
line is the decay curve, the blue dotted vertical line marks
t=2h post-dose (corresponding to concentration mea-
surements from organs) and the red dashed line indicates
method limit of detection (LOD). The equation of each
decay curve is shown on each plot. (For interpretation of the
references to colour in this ﬁgure legend, the reader is re-
ferred to the web version of this article.)
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feathers reﬂected external and/or internal contamination, it is note-
worthy that we only detected ﬂuoxetine in the liver of one control bird
(and then only at a concentration close to the detection limit). This
suggests that control birds were not routinely ingesting ﬂuoxetine.
Furthermore, the ﬂuoxetine concentration was around fourfold higher
in regrown feathers from dosed than from control birds (Mann Whitney
U test, U=0, p=0.002; n=11 ﬂuoxetine-treated and n=5 control
birds; Fig. 5). Some of the higher ﬂuoxetine residues in ﬂuoxetine-
treated bird regrown feathers are likely due to ﬂuoxetine deposition
into feathers from systemic circulation, analogous to deposition into
hair following oral administration in mammals (Lefebvre et al., 1999;
Fisichella et al., 2014). However, preen gland secretion is a suggested
excretory route for persistent organic pollutants (Solheim et al., 2016)
and preen oil is a major source of external feather contamination for
highly lipophilic contaminants (Jaspers et al., 2008; Solheim et al.,
2016). Therefore, although ﬂuoxetine is less lipophilic than many
persistent organic pollutants, we cannot rule out the possibility that
surface contamination was reinforced in dosed birds by residues in
preen oil.
There were no signiﬁcant correlations between feather and organ
ﬂuoxetine concentrations (see SI, Table S6). Norﬂuoxetine was not
detected in any regrown-feathers from control birds but was found in
four of the ﬂuoxetine-treated birds (concentration range of
0.74–1.25 ng g−1). This may possibly be an additional indicator of de-
position of the compound from the plasma into feathers in treated birds,
although it is unclear why norﬂuoxetine was not found in regrown
feathers from all the chronically dosed birds. Overall, our results sug-
gest that feathers could be used to assess the occurrence of exposure to
ﬂuoxetine in wild birds, although currently the mechanism of con-
tamination (whether via systemic circulation or preen oil) is unclear.
Further work is needed to elucidate the dynamics between exposure
and deposition of residues into and onto feathers.
Fluoxetine was also detected in wild-grown feathers from most (21
of 25) of the starlings brought into captivity, whilst norﬂuoxetine was
not detected in any wild-grown feathers. The frequent detection of
ﬂuoxetine in wild-grown feathers may in part have resulted from
surface contamination during the week-long dosing of the experimental
birds that occurred before the wild-grown feathers were plucked or, in
ﬂuoxetine-treated birds, from ﬂuoxetine in preen oil applied to the
feathers. Indeed, based on the higher rates of ﬂuoxetine observed in
ﬂuoxetine-treated compared to control bird regrown feathers (see
Fig. 5), this seems plausible. However, it seems unlikely that external
(surface) contamination would account for all the observed residues in
wild-grown control bird feathers, especially since two of the three
highest concentrations were in birds from the wild control group, and
one of these was the highest concentration in any feather (wild-grown
or regrown) that we analysed. The data suggest that some individuals
may have been exposed to ﬂuoxetine in the wild, likely between late
May and early September in the summer preceding the experiment, as
all feathers are moulted and regrown over approximately 100 days in
Eurasian starlings (Rothery et al., 2001). Further analyses of feathers
from free-living birds are needed to conﬁrm such exposure and assess
its prevalence.
4. Conclusions
Our results suggest that ﬂuoxetine exposure in wild birds can be
monitored by analysing residues in liver and kidney tissues harvested
from dead birds, and possibly in feathers from live or dead birds. Any
such monitoring presents challenges. Residues in the liver and kidney
are relatively labile, becoming undetectable several days post-exposure.
Measured concentrations are also likely to vary markedly with both
magnitude of exposure and the period between the last exposure event
and death. Internal feather residues (those incorporated into the feather
structure) provide an indication of exposure during the period when
feathers are regrown (Daniel and Wojcikowski, 1997) and the processes
by which deposition into feathers occurs can be complex (Bortolotti,
2010). There is also the potential to confuse external and internal
contamination (Jaspers et al., 2007), leading to overestimation of in-
ternal residue concentrations. However, even if the contribution of
preen oil and deposition by systemic circulation to feather ﬂuoxetine
concentrations cannot be diﬀerentiated, valuable data regarding ex-
posure on a presence/absence basis can still be collected. If internal and
external concentrations could be diﬀerentiated, it might then be pos-
sible to collect additional information on the variability of exposure
over time within the feather growth period, by analysing sequential
sections from the same feather. Further work is needed to determine the
extent to which feathers can be used to characterise the scale of wild
bird exposure to ﬂuoxetine, and indeed other pharmaceuticals, espe-
cially those species whose foraging strategies put them at particular risk
of exposure. Finally, our analysis of wild feathers suggests that exposure
of free-living starlings to ﬂuoxetine does occur. This is of concern, as
ﬂuoxetine has been found to alter Eurasian starling behaviours at a dose
less than half of the environmentally relevant dose used in the present
study (Bean et al., 2014). Although the likelihood and signiﬁcance of
eﬀects in free-living birds resulting from pharmaceutical exposures re-
mains to be determined, the implementation of pharmaceutical-ap-
propriate biomonitoring campaigns could signiﬁcantly further our un-
derstanding in this area.
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